The Naval Medical Research Center intends to award a sole source contract under authority of FAR Part 6.302-1 to Roche Diagnostics, The LightCycler URACIL-DNA GLYCOSYLASE, Faststart UNG produced by Roche is a component of reagents being produced by NMRC/BDRD for biological defense applications. These reagents are employed by a variety of Navy Department of Defense, and other US Government agencies for the detection and identification of biological warfare agents. Additionally, these reagents are currently deployed globally for operational use. The development process included extensive testing of various reagent components to produce the best combination. The LightCycler Faststart UNG produced by Roche is one of those components. Switching to UNG from another vendor would invalidate all previous optimization and evaluation would result in reduced performance of the reagents. This is unacceptable to the agencies that employ the current reagents in ongoing operations.

There are no set-aside restrictions for this requirement. The intended procurement will be classified under North American Industry Classification System (NAICS) 325413. This Notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However parties interested in responding to this notice  shall submit by email Only as a MS Word or Adobe PDF attachment to [email protected] No phone calls will be accepted.